Company reports strong financial results for 2022 with 27% revenue growth in 2022 and significantly increased margins Growth driven by launch of Letybo® and its catalytic effect on the existing portfolio as well as strong market growth Continued market share gains, strategic mid-term…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.